Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts

Citation
Ec. Keeley et al., Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts, J AM COL C, 38(3), 2001, pp. 659-665
Citations number
31
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ISSN journal
07351097 → ACNP
Volume
38
Issue
3
Year of publication
2001
Pages
659 - 665
Database
ISI
SICI code
0735-1097(200109)38:3<659:LCOAPO>2.0.ZU;2-W
Abstract
OBJECTIVES The purpose of this study was to examine the long-term clinical outcome after percutaneous intervention of saphenous vein grafts (SVG) and to identify the predictors of major adverse cardiac events (MACE). BACKGROUND Percutaneous interventions of SVGS have been associated with mor e procedural complications and higher restenosis rates compared with interv entions on native vessels. METHODS From 1993 to 1997, 1,062 patients underwent percutaneous interventi on on 1,142 SVG lesions. Procedural, in-hospital and long-term clinical out comes were recorded in a database and analyzed. RESULTS In-hospital MACE occurred in 137 patients (13%) including death (8% ), Q-wave myocardial infarction (MI) (2%) and coronary artery bypass surger y (3%). Late MACE occurred in 565 patients (54%) including death (9%), Q-wa ve MI (9%) and target vessel revascularization (36%). Any MACE occurred in 457 (43%) patients. Follow-up was available in 1,056 (99%) patients at 3 +/ - 1 year. Univariate predictors were restenotic lesion (odds ratio [OR]: 2. 47, confidence interval [CI]: 1.13 to 3.85, p = 0.0003), unstable angina (O R: 1.99, CI: 1.27 to 2.91, p = 0.04) and congestive heart failure (CHF) (OR : 1.97, CI: 1.14 to 3.24, p = 0.02) for in-hospital MACE, and peripheral va scular disease (PVD) (OR: 2.18, CI: 1.34 to 3.44, p = 0.002), intra-aortic balloon pump placement (OR: 2.08, CI: 1.13 to 3.85, p = 0.02) and previous MI (OR: 1.97, CI: 1.14 to 3.25, p = 0.007) for late MACE. Independent multi variate predictors for late MACE were restenotic lesion (relative risk [RR] 1.33, p = 0.02), PVD (RR: 1.31, p = 0.01), CHF (RR: 1.42, p = 0.01) and mu ltiple stents (RR: 1.47, p = 0.004). Angiographic follow-up was available f or 422 patients. Angiographic restenosis occurred in 122 (29%) of stented S VGS and 181 (43%) of nonstented SVGS (p = 0.04). Stent implantation did not confer a survival benefit. CONCLUSIONS Despite the use of new interventional devices, SVG intervention s are associated with significant morbidity and mortality; SVG stenting is not associated with better three-year event-free survival. This may be due to progressive disease at nonstented sites. (C) 2001 by the American Colleg e of Cardiology.